Swedbank
ABCL icon

Swedbank’s AbCellera Biologics ABCL Stock Holding History

Swedbank’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,951,940
Closed -$28M – 754
2021
Q4 		$28M Buy
1,951,940
+146,930
+8% +$2.23M 0.05% 281
2021
Q3 		$36.2M Buy
1,805,010
+953,860
+112% +$16.9M 0.07% 242
2021
Q2 		$18.7M Buy
851,150
+268,650
+46% +$7.41M 0.04% 364
2021
Q1 		$19.8M Buy
+582,500
New +$23.2M 0.04% 334

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

Swedbank's ABCL Position: Q1 2022 in Review

Swedbank sold out of AbCellera Biologics (ABCL) in Q1 2022, closing a stake of 1,951,940 shares — an estimated $28M sold.

Swedbank first reported a position in ABCL in Q1 2021 and held it in 4 quarters. The position peaked at $36.2M in Q3 2021. 130 funds tracked by Wall St. Rank hold ABCL as of Q1 2022.

  • Swedbank reported no remaining AbCellera Biologics position as of Q1 2022 after selling out during the quarter.
  • Swedbank sold 1,951,940 AbCellera Biologics shares in Q1 2022, an estimated $28M.
  • Swedbank first reported a position in AbCellera Biologics in Q1 2021 and held it in 4 quarters.
  • Swedbank's AbCellera Biologics position peaked at $36.2M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2022.

Based on Swedbank's 13F filing for Q1 2022, filed 6 Dec 2024.